Less than half of those who tested positive for HIV in Pretoria were aware of their HIV status. As such they would not have ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

Six-monthly HIV drug, lenacapavir, reduced HIV incidence by 96 per cent in trial. Affordability and supply remain key hurdles for rollout.

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

Gilead and Merck said their once-weekly pill to treat HIV resulted in a comparable level of viral suppression compared to a ...

With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...

Doctors and front-line workers are watching closely as HIV rates increase significantly in Alberta.An annual Alberta Health ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...